NICE has announced they will begin a phased restart of publishing guidance, whilst SMC meetings are ...
Read moreIRP is a pricing mechanism where the price of a drug in one country is set or adjusted in relation t...
Read moreWe received fabulous feedback, with responses from at least 15 industry executives across global pha...
Read moreWhilst many businesses are currently working remotely, up-skilling your workforce through interactiv...
Read moreCAR T-cell therapies and speculation in the pricing and market access implications for the lymphoma ...
Read moreArrangements made between manufacturers and payers which are being implemented for innovative treatm...
Read moreGiven the shutdown occurring in response to COVID-19, payers and HTA bodies are struggling to adjust...
Read moreNICE confirmed that they will be prioritising work that is therapeutically critical or relates to ad...
Read more"Payer" generally refers to people or bodies other than the patient that finance or refund the cost ...
Read moreDifferences in market access and reimbursement processes are an important factor in determining the ...
Read more